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Objective:This study aimed to evaluate circulating natriuretic peptides (NP) concentration
in obese and non-obese children and adolescents with and without obstructive sleep apnea
(OSA), and their levels following OSA treatment.
Methods:Subjects with habitual snoring and symptoms suggestive of OSA were recruited.
They underwent physical examination and overnight polysomnography (PSG). OSA was
diagnosed if obstructive apnea–hypopnea index (OAHI) was ≥1/h. Fasting serum atrial
natriuretic peptide (ANP) and brain natriuretic peptide (BNP) were taken after overnight
PSG. The subjects were divided into obese, non-obese, with and without OSA groups for
comparisons.
Results: One hundred fourteen children (77 were boys) with a median [interquartile range
(IQR)] age of 10.8 (8.3–12.7) years (range: 2.4–11.8 years) were recruited. Sixty-eight sub-
jects were found to have OSA. NP levels did not differ between subjects with and without
OSA in both obese and non-obese groups. Stepwise multiple linear regressions revealed
that body mass index (BMI) z -score was the only independent factor associated with
NP concentrations. Fifteen children with moderate-to-severe OSA (OAHI >5/h) under-
went treatment and there were no significant changes in both ANP and BNP levels after
intervention.
Conclusion: Body mass index rather than OSA was the main determinant of NP levels in
school-aged children and adolescents.
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INTRODUCTION
Obstructive sleep apnea (OSA) is characterized by repeated
episodes of complete or partial upper airway occlusion during
sleep. Childhood OSA if remains untreated can lead to behavioral
changes and abnormalities in blood pressure control and ventric-
ular function (1–4). This condition is increasingly recognized, and
the prevalence in children is around 5% (5).
Both atrial natriuretic peptide (ANP) and brain natriuretic pep-
tide (BNP) are neuro-hormones released by the cardiac ventricles
and play an essential role in electrolytes regulation and water bal-
ance (6). Increased NP concentrations can decrease heart rate and
blood pressure by regulating sympathetic activity and the renin–
angiotensin–aldosterone pathway (7). These hormones may play
an important role in OSA-related cardiovascular abnormalities.
However, studies that examined ANP and BNP levels in adults with
OSA have reported conflicting results (8–11). Maillard et al. doc-
umented a significant negative correlation between ANP and OSA
severity (8). BNP levels were found to reduce markedly after the
initiation of continuous positive airway pressure (CPAP) therapy
(9). On the other hand, Svatikova et al. found no significant dif-
ference in both ANP and BNP levels in adult subjects with and
without OSA (10). Similarly, Patwardhan et al. reported no age-
and sex-adjusted significant difference in BNP between OSA adults
and normal healthy subjects (11). Furthermore, Maeder et al. did
not find significant association between OSA severity and a pro-
hormone of BNP at baseline and after initiation of CPAP treatment
(12, 13). Similar research in pediatrics is limited and the results
are also contradictory. Kaditis et al. (14) reported no significant
difference in evening or morning BNP levels between children
with and without OSA while Sans-Capdevila et al. (15) docu-
mented higher plasma BNP levels in OSA children. A preliminary
intervention study showed significant decrease in BNP following
adenotonsillectomy in children with OSA (16). Further studies
were therefore needed to better delineate the relationship between
OSA and natriuretic peptide (NP) levels.
The aims of this study were to compare plasma concentra-
tions of ANP and BNP between obese and non-obese children
and adolescents with and without OSA, and to determine whether
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treatment for OSA would alter their levels. We hypothesized that
body mass rather than OSA severity was the main determining
factor associated with NP levels.
MATERIALS AND METHODS
SUBJECTS
Children with habitual snoring and symptoms suggestive of OSA
were consecutively recruited from our Pediatric Respiratory, Sleep
Disorder, and Obesity Clinic. Patients were excluded from the
study if they were active smokers (self-reporting and confirmed
by parents), had inter-current upper respiratory tract or systemic
infection within 4 weeks of recruitment, suffered from neuromus-
cular disorder such as Duchenne muscular dystrophy, craniofacial
anomalies, cardiovascular diseases, syndromic disorder, for exam-
ple, Down syndrome, or if they had previously undergone upper
airway surgery. Each subject and their parent completed a sleep-
disordered breathing questionnaire on nighttime and daytime
symptoms of OSA and past personal medical history (17). The
study was approved by the Clinical Research Ethics Committee
of the Chinese University of Hong Kong and informed written
consent from the parents was obtained at the beginning of the
assessment.
ANTHROPOMETRY AND PHYSICAL ASSESSMENT
The weight and standing height of the subjects were measured with
a calibrated weighing scale and stadiometer by standard anthro-
pometric methods (18). Body mass index (BMI) was calculated
as weight/height2 (kg/m2) and z-score derived using local refer-
ence (19). Children were defined as obese if their BMI z-score was
≥1.65, corresponding to the 95th percentile, relative to age and
gender. Resting systolic blood pressure (SBP) and diastolic blood
pressure (DBP) were measured by an oscillometric device (Accu-
torr Plus, Datascope Inc., Montvale, NJ, USA) with the subject
sitting after 15 min rest. Three consecutive measurements were
taken at 5-min intervals and average of the three readings was
recorded.
POLYSOMNOGRAPHY
An overnight polysomnography (PSG) was performed on each
subject. Siesta ProFusion II PSG system (Compumedics Telemed
PTY Ltd. Abbotsford, Australia) was used to record the follow-
ing parameters: electroencephalogram from four leads (C3/A2,
C4/A1), bilateral electrooculogram, electromyogram of mentalis
activity, and bilateral anterior tibialis. Respiratory movements of
the rib cage and abdomen were measured by pneumatic effort
belt. Electrocardiogram and heart rate were continuously recorded
from two anterior chest leads. Arterial oxyhemoglobin saturation
(SaO2) was monitored by an oximeter (Ohmeda Biox 3900 Pulse
Oximeter). Respiratory airflow pressure signals were measured at
the anterior nares and connected to a pressure transducer. Snor-
ing was assessed by a snoring microphone placed near the throat.
Body position was recorded by a body position sensor. Obstructive
apnea (OA) was defined as absence of airflow with persistent respi-
ratory effort lasting longer than two baseline breaths, irrespective
of SaO2 changes. Obstructive apnea index (OAI) was defined as
the number of OA per hour of sleep. Hypopnea was defined as
a reduction of 50% or more in the amplitude of the airflow sig-
nal. It was only quantified if longer than two baseline breaths
and associated with oxygen desaturations of at least 3% and/or
arousals. Obstructive apnea–hypopnea index (OAHI) was defined
as the total number of obstructive apneic and hypopneic episodes
per hour of sleep. Arousal was defined by standard criteria (20).
We defined OSA as OAHI≥1 episode per hour of sleep (21). Sub-
jects who had an OAHI value <1 episode per hour of sleep were
grouped as non-OSA.
LABORATORY MEASUREMENTS
All subjects had fasting blood samples taken in the morning fol-
lowing overnight PSG. Plasma proANP(1–98) was measured by
enzyme-linked immunosorbent assay (Biomedica Medizinpro-
dukte GmbH & Co KG, Wien, Divischgasse 4, Germany) (22)
and BNP was measured by chemiluminescent immunoassay using
the ADVIA Centaur Analyzer (Siemens Healthcare Diagnostics,
Deerfield, IL, USA) (23). The detection limit and the inter-assay
coefficients of variation for proANP and BNP were 50 pmol/L,
7.2% at 436 and 0.58 pmol/L, 1.9% at 8.5 pmol/L, respectively.
TREATMENT AND FOLLOW-UP
Subjects with moderate-to-severe OSA, defined as OAHI >5/h,
were offered adenotonsillectomy after assessment by an otorhino-
laryngologist. Patients who refused surgery or in whom surgical
intervention was not indicated as defined by pre-determined cri-
teria (small tonsils; tonsils that do not extend beyond the anterior
tonsillar pillar and small adenoids; adenoids, which occupy <25%
of post-nasal space with minimal OSA symptoms or poorly con-
trolled allergic rhinitis with supine nasal obstruction) were offered
alternative treatment options including CPAP and/or nasal corti-
costeroids therapy (24). All subjects underwent repeat assessment
12 weeks after the operation or commencement of CPAP and or
nasal corticosteroids. Subjects with mild OSA (OAHI 1–5/h) were
followed-up in our sleep disorder clinic to monitor their disease
progression but no further blood sampling was carried out.
STATISTICAL ANALYSIS
The subjects were divided into four groups (non-obese without
OSA, non-obese with OSA, obese without OSA, and obese with
OSA). Mean± SD, median [interquartile range (IQR)], and num-
ber (percentage) were presented for parametric, non-parametric,
and categorical data, respectively. Parametric and non-parametric
data were compared using one-way analysis of variance (ANOVA)
and the Kruskal–Wallis test, respectively. For parametric data,
Tukey or Games–Howell method (depending on the agreement of
the assumption of variance) was used for post hoc pairwise com-
parisons. For non-parametric data, Mann–Whitney U tests with
adjusted p values (Bonferroni correction, significance at p< 0.05/6
pairwise comparisons= 0.008) were used for pairwise compar-
isons. The Chi-square test was used to assess the differences in
proportion between the four groups with Bonferroni correction.
Stepwise multiple regression analyses were used to assess the cor-
relates of ANP and BNP. As BNP data were right-skewed, the data
was log-transformed to obtain a normal distribution before enter-
ing into regression models. The following variables were put into
the stepwise regression analyses for selection: age, gender, BMI z-
score, OAI, OAHI, and arousal index. Two-way ANOVA was used
to assess the interactive effect of obesity and OSA on NP. For
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the comparison of parameters before and after treatment of OSA,
Wilcoxon signed-rank test was used to determine the differences.
SPSS for Windows 14 (SPSS, Inc., Chicago, IL, USA) was used in
the analysis.
RESULTS
One hundred fourteen subjects were invited and all agreed to par-
ticipate in this study. There were 77 boys and the median (IQR)
age of the subjects was 10.8 (8.3–12.7) years. The demographic
characteristics, laboratory results, and PSG parameters were sim-
ilar between boys and girls. All subjects had normal physical
examination.
Sixty-eight subjects satisfied the diagnostic criteria for OSA
and 42 of them were boys. The clinical characteristics of obese
and non-obese subjects with and without OSA were compared
in Table 1. Obese subjects had lower plasma ANP and BNP lev-
els than non-obese subjects in both non-OSA and OSA groups,
though this comparison did not reach statistical significance
amongst children with OSA (Table 1). ANP and BNP levels were
not different between OSA and non-OSA subjects in both obese
and non-obese subgroups. Stepwise multiple regression analysis
identified BMI z-score as the only factor significantly associ-
ated with ANP [β(SE)=−224.0(52.6), p< 0.001] and log-BNP
[β(SE)=−0.24(0.09), p= 0.007]. The interactive effect of BMI z-
score and OAHI on plasma ANP and BNP concentration was not
significant (p= 0.588 and p= 0.914, respectively).
Of the 68 OSA subjects, 39 had an OAHI >5/h and of whom
15 agreed for treatment at our institution and returned for re-
assessment. Twelve had adenotonsillectomy and one obese subject
was started on CPAP. Two subjects who had small tonsils but
reported to have allergic rhinitis symptoms were given 3 months of
nasal spray corticosteroids. Twenty-four subjects did not undergo
repeat assessment. There were, however, no significant differences
in demographic characteristics, laboratory results, and PSG para-
meters between those who had repeat assessment and those who
did not. For the 15 subjects who returned for repeat assessment,
2 had missing BNP level data. There were no significant changes
in ANP and BNP concentrations following intervention for OSA
(Table 2).
DISCUSSION
In this study, we failed to demonstrate any relationship between
NP levels and OSA severity at both baseline and following inter-
vention for OSA. We found significantly lower plasma ANP and
BNP levels in obese than non-obese subjects for the non-OSA
group. Furthermore, a trend of lower plasma NP levels in obese
subjects was also observed for children with OSA. BMI z-score
rather than OSA severity was the only independent predictor for
ANP and BNP levels.
Atrial natriuretic peptide and BNP are NPs produced by
myocytes of the ventricles and they are released in response to
increased cardiac pressure and volume load (25). Children with
Table 1 | Demographic, laboratory, and sleep parameters of the subjects.
Non-obese Obese p
Non-OSA (group 1) OSA (group 2) Non-OSA (group 3) OSA (group 4)
(n=26) (n=30) (n=20) (n=38)
Age (years) 9.1±3.1 9.9±4.3 11.4±3.2 11.2±3.2 0.056
Male gender, n (%) 19 (73.1) 20 (66.7) 16 (80.0) 22 (57.9) 0.334
Weight (kg)c 29.3±10.1 34.9±17.8 63.7±16.3 61.5±21.4 <0.001
Height (m)b 1.32±0.16 1.34±0.24 1.51±0.14 1.47±0.15 <0.001
BMI z -scorec −0.004±0.926 0.297±1.051 2.209±0.313 2.309±0.472 <0.001
SBP (mmHg)c 101±12 111±17 121±13 123±16 <0.001
DBP (mmHg) 61±9 65±8 68±6 70±9 0.002
OAI/ha,d 0 (0–0) 1.7 (0.5–7.1) 0 (0–0.1) 1.0 (0.2–4.6) <0.001
OAHI/ha,d 0.2 (0–0.5) 9.4 (4.2–19.8) 0.2 (0.1–0.5) 4.5 (2.0–14.2) <0.001
Arousal index/ha 5.7 (3.9–9.9) 8.9 (6.6–14.5) 5.3 (4.0–7.8) 6.0 (4.4–13.6) 0.007
ANP (fmol/ml)b 2292±948 2026±656 1467±655 1660±658 <0.001
BNP (pmol/l) 3.1 (1.6–7.6) 3.7 (1.6–9.6) 1.4 (0.3–5.3) 2.8 (0.7–5.4) 0.067
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; OAI, obstructive apnea index; OAHI, obstructive apnea–hypopnea index; ANP, atrial
natriuretic peptide; BNP, brain natriuretic peptide.
Data were presented as mean±SD, median (IQR), and number (percentage) for parametric, non-parametric, and categorical data, respectively.
p values were obtained from ANOVA, Kruskal–Wallis test, and Chi-square test table for parametric, non-parametric, and categorical data, respectively.
Post hoc analyses, Tukey HSD, or Games–Howell method for the parametric variables and Mann–Whitney U test with adjusted p values (significant at p<0.008) for
non-parametric variables.
aSignificant difference between group 1 and 2.
bSignificant difference between group 1 and 3.
cSignificant difference between group 2 and 4.
dSignificant difference between group 3 and 4.
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Table 2 | Laboratory and PSG parameters of the 15 subjects before
and after treatment.
Pre Post p
Age (years) 10.8 (6.6–13.3) 11.1 (7.4–14.8) <0.001
Weight (kg) 49.5 (18.0–64.1) 51.4 (20.7–72.6) 0.073
Height (m) 1.45 (1.15–1.60) 1.53 (1.19–1.61) 0.010
Body mass index
(kg/m2)
21.1 (15.2–25.6) 22.8 (15.9–26.3) 0.112
Body mass index
z -score
1.20 (−0.18–1.91) 1.40 (0.17–1.83) 0.394
Systolic blood pressure
(mmHg)
111 (102–129) 111 (103–126) 0.432
Diastolic blood pressure
(mmHg)
67 (59–70) 63 (60–71) 0.636
Obstructive apnea
index/h
7.8 (1.2–13.7) 0 (0–0) <0.001
Obstructive
apnea–hypopnea
index/h
19.5 (9.6–33.3) 0.8 (0.5–1.5) <0.001
Arousal index/h 9.1 (6.3–22.2) 4.8 (2.6–7.8) <0.001
ANP (fmol/ml) 1861 (1121–2289) 1528 (968–2055) 0.112
BNP (pmol/l) (n=13) 4.1 (1.3–7.0) 2.5 (0.5–5.4) 0.173
Data were presented as median (IQR). p values were obtained from Wilcoxon
signed-rank tests.
ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide.
heart failure or pulmonary hypertension have increased ANP
and BNP levels (26). NP exert potent lipolytic effects in isolated
human fat cells and adipocytes (27). Birkenfeld et al. documented
that ANP could activate hormone-sensitive lipase in human fat
cells and leads to lipolysis (28). Therefore, increased NP could
inhibit lipid accumulation in adipose tissue and skeletal muscle
and decrease cardiovascular risk (29).
The current literature examining NP in subjects with OSA
has conflicting results. In our study, both ANP and BNP were
documented to be closely associated with BMI only. We failed
to show different NP levels in OSA and non-OSA subjects. Fur-
thermore significant association between their plasma levels with
variables of OSA such as OAHI, oxygen saturation nadir, and
arousal index was not demonstrated in regression analysis. Our
result was consistent with findings reported by Kaditis et al. (14)
who showed no significant difference in morning and evening BNP
levels between children with OSA and normal controls, though
they did find a significantly greater overnight increase in BNP lev-
els amongst subjects with moderate-to-severe OSA. In contrast,
Sans-Capdevila et al. (15) documented higher morning BNP lev-
els in OSA children compared with normal controls. Different
age range, inclusion of obese subjects, and milder OSA disease
amongst our subjects in our study could explain the discrepancy.
The use of snoring non-OSA subjects for comparison may be
another reason to explain why we failed to show significant dif-
ferences in NP levels between our study groups. In the study by
Sans-Capdevila et al. the authors also failed to show significant
difference in BNP levels between OSA and subjects with pri-
mary snoring (15). There is on-going argument related to whether
primary snoring is indeed a benign entity. In our previous publica-
tions, we found higher blood pressure and abnormal endothelial
function in children with primary snoring compared to healthy
controls (30, 31). Therefore, using primary snorers as a compar-
ison group may dilute the overall difference in ANP and BNP
levels.
Lower ANP and BNP levels were found in obese subjects. Our
results were consistent with a previous study on NP and obesity
in children where lower BNP levels were documented in obese
children (32). Similar results have also been reported in several
adult studies (33–35). NP possess lipolytic properties (27) and
hence it might play a role in weight loss or weight maintenance.
Furthermore, adipose tissue is a source of NP clearance receptors,
therefore, increase in adipose tissue increases the clearance of NP
and low NP levels would be expected (36).
Following intervention for OSA, no significant change in both
ANP and BNP levels were found. However a previous study con-
ducted in children with OSA demonstrated a significant reduction
in BNP levels 4–6 months after adenotonsillectomy. The discrep-
ancy may be attributed to our shorter follow-up period (16).
Another study showed that BNP levels decreased significantly after
adenotonsillectomy in young children with OSA (37). The age
range of subjects in the study was much lower compared to our
cohort. Their mean age was 19.7 months. Furthermore, the sub-
jects had more severe OSA disease, their mean AHI was 16.9/h. In
an adult study that involved patients with OSA with and without
cardiovascular disease, the authors did not find significant changes
in ANP or BNP levels following CPAP (13).
There were several limitations in our study. First, we man-
aged to obtain post-intervention data in only 15 out of 39 OSA
subjects. There were however, no significant differences in demo-
graphic, laboratory, and sleep apnea characteristics between those
who underwent and those who did not have repeat assessment.
Second, we could have selected a biased sample as we recruited
our subjects from attendants to our Pediatric Respiratory, Sleep
Disorder, and Obesity Clinic. Boys were more likely to be obese
and this could explain the male preponderance seen in this study.
Lastly, we did not have a control group of non-snoring chil-
dren for comparison. However, it is practically difficult to recruit
healthy non-snoring children for overnight sleep study and blood
sampling.
In summary, our results demonstrated that weight rather than
OSA was the important determining factor for ANP and BNP
levels in both obese and non-obese school-age children.
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